Ropivacaine is an aminoamide local anesthetic drug marketed by AstraZeneca under the trade name Naropin. It exists as a racemate of its S- and R-enantiomers, although the marketed form is supplied only as the purified S-enantiomer.
Ropivacaine is indicated in adult patients for the induction of regional or local anesthesia for surgery or acute pain management.
Soonchunhyang University Seoul Hospital, Seoul, Korea, Republic of
University of Marburg Department of Anaesthesia And Intensive Care Medicine, Marburg, Germany
Guangzhou Military Region General Hospital, Department of Anesthesiology, Guangzhou, Guangdong, China
Guangzhou Military Region General Hospital, Department of Anesthesiology, Guangzhou, Guangdong, China
Massachusetts General Hospital, Boston, Massachusetts, United States
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Brigham & Women's Hospital, Boston, Massachusetts, United States
Centre hospitalier départemental Vendée, La Roche sur Yon, France
Guangzhou Military Region General Hospital, Department of Anesthesiology, Guangzhou, Guangdong, China
DMC Surgery Hospital, Madison Heights, Michigan, United States
Texas Children't Hospital, Houston, Texas, United States
Asklepieion Hospital of Voula, Athens, Attica, Greece
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.